Triple vírica y alergia al huevo / MMR Vaccine and egg alergic

Las vacunas constituyen una de las medidas másefectivas en la lucha contra las enfermedades transmisibles.La utilización de las mismas de forma sistemáticapermite el control e incluso la erradicaciónde algunas de estas enfermedades.Uno de los objetivos de la Organización Mundialde la Salud es la erradicación del sarampión en 3 desus regiones entre las que se incluye la europea. Comoconsecuencia de lo anterior, se han desarrolladoplanes de actuación específicos en nuestro pais queincluyen entre sus estrategias la de alcanzar una altacobertura vacunal. La vacuna del sarampión está incluidaen el calendario vacunal en nuestro país desde1981, administrándose de forma conjunta a las dela rubéola y la parotiditis en forma de vacuna trivalente.Esta vacuna se obtiene mediante cultivo del virusen fibroblastos de embrión de pollo. La posibilidadde desarrollar una reacción anafiláctica tras suadministración en niños alérgicos al huevo aceleró eldesarrollo de otras vacunas desarrolladas en célulasdiploides humanas que se han venido utilizando ensustitución de la TV tradicional. Sin embargo, el ceseen la producción de una de ellas y la falta de disponibilidadde la otra, que además no incluye cepas delvirus de la parotiditis, ha supuesto el resurgir de lacontroversia en torno a la utilización de esta vacunaen caso de alergia al huevo

Vaccines are one of the most powerfull tools availablein the battle against infectious agents. The useof systematic vaccinnation allows both the controland erradication of some infectious diseases.As a primary target, regional measles eliminationinitiatives have been stablished in three of the WHOregions, being the European Region one of them.Therefore, specific actuation plans are being developedin our country, these national plans include intheir strategy to obtain a high coverage inmunization.In our country, since 1981, measles vaccine isincluded in the vaccine schedule, wich is simultaneouslydelivered with rubella and mumps vaccine(MMR). Measles virus used in the MMR is grown incultures of fibroblasts from chicken embryos. Therisk of anaphylaxis in egg allergic individuals aftervaccination promoted the research of two vaccinesgrown in diploid human cells (Triviraten and Moruviraten).These vaccines have been administrated toegg allergic patients in the last years in substitutionof traditional MMR. Taking into account that triviratenworld wide production has ceased and that moruviratennot only run out of stocks but also doesn`tinclude mumps vaccine, the controversial about theuse of MMR in egg allergic individuals has reappeared

Effect of gender on reporting of MMR adverse events in Saudi Arabia.

We evaluated the safety of a measles-mumps-rubella (MMR) immunization campaign for Saudi children (age range: 6-13 years) and gender differences in reporting post-MMR adverse events. After vaccinations were administered, we monitored 160 schools for 14 days and 19 hospitals in the 8 cities under study for 10 weeks. Incidence rates were: all MMR adverse events, 26.5/10,000 MMR vaccines (significantly higher in females than males); Urabe strain aseptic meningitis, 1.0/295,000; fever, 40.2/10,000 (females) and 0.9/10,000 (males); and parotitis, 5.4/10,000 (females) and 0.9/10,000 (males). Combined MMR vaccine containing the Urabe mumps strain was safe for children aged 6-13 years. Gender differences regarding reactogenicity were evident and should be considered when designing future studies.